Compare · MDGL vs MRK
MDGL vs MRK
Side-by-side comparison of Madrigal Pharmaceuticals Inc. (MDGL) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGL and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $314.90B, about 24.7x MDGL ($12.76B).
- Over the past year, MDGL is up 65.7% and MRK is up 59.4% - MDGL leads by 6.2 points.
- MRK has been more active in the news (14 items in the past 4 weeks vs 5 for MDGL).
- MRK has more recent analyst coverage (25 ratings vs 22 for MDGL).
- Company
- Madrigal Pharmaceuticals Inc.
- Merck & Company Inc.
- Price
- $553.33+1.41%
- $127.48-0.14%
- Market cap
- $12.76B
- $314.90B
- 1M return
- +10.36%
- +10.60%
- 1Y return
- +65.69%
- +59.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 5
- 14
- Recent ratings
- 22
- 25
Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest MDGL
- Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
- Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Director Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)
- Director Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)
- Director Fouse Jacqualyn A was granted 454 shares, increasing direct ownership by 41% to 1,551 units (SEC Form 4)
- Director Daly James M was granted 454 shares, increasing direct ownership by 17% to 3,081 units (SEC Form 4)
- Director Brennan Daniel J. was granted 404 shares, increasing direct ownership by 42% to 1,371 units (SEC Form 4)
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.